100 filings
Page 4 of 5
8-K
8z4vp jyreh
26 Mar 19
Other Events
4:58pm
10-K
8moy9wn2e11xlugv
19 Mar 19
Annual report
4:23pm
8-K
46dkt5obuwyevobz
19 Mar 19
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results
4:10pm
8-K
eawybe pt74378e
13 Mar 19
Termination of a Material Definitive Agreement
1:19pm
8-K
lmm49r0w
4 Mar 19
Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating
2:25pm
8-K
9rue0 4awt7nn
28 Feb 19
Other Events
3:26pm
8-K
36u75ea
19 Feb 19
Departure of Directors or Certain Officers
5:09pm
8-K
jbd xdtd0
4 Feb 19
Other Events
5:00pm
8-K
tvi7zb8xwzowxe k0a
19 Dec 18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:50pm
8-K
61ap0dn
29 Nov 18
Principia Biopharma Reports Positive PRN1008 Phase 2Top-Line Results and Initiates Phase 3 Pemphigus Program
9:51pm
10-Q
tyymb
6 Nov 18
Quarterly report
4:47pm
8-K
pvebpp7421kljo 78
6 Nov 18
Principia Biopharma Reports Third Quarter Financial Results
4:06pm
8-K
imjjmoj
29 Oct 18
Principia Biopharma Appoints Dolca Thomas, M.D. as Chief Medical Officer
5:26pm
8-K
ogisk0g
18 Oct 18
Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168
5:27pm
8-K
71r 6jckzcfnk4h
18 Sep 18
Departure of Directors or Certain Officers
12:00am
S-8
u6w9qnkpgk6d7n 9467
18 Sep 18
Registration of securities for employees
12:00am
424B4
jugghp3
17 Sep 18
Prospectus supplement with pricing info
12:00am
EFFECT
1ukmsu
13 Sep 18
Notice of effectiveness
12:00am
CT ORDER
9za779ix4b99urqtsig
13 Sep 18
Confidential treatment order
12:00am